Abstracts tagged "Disease Activity"

Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Martin Bergman¹, Yusuf Yazici ², Laura Coates ³, Josef Smolen ⁴, M. Elaine Husni ⁵, Sven Richter ⁶, Lichen Teng ⁶ and Arthur Kavanaugh ⁷, ¹Drexel University College of Medicine, Stockholm, Sweden, ²New York University School of Medicine, New York, ³University of Oxford, Oxford, United Kingdom, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁶Celgene Corporation, Summit, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
Abstract Number: 468 • 2019 ACR/ARP Annual Meeting
Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status
Shumaila Iqbal¹, Linda Burns ², Joseph Grisanti ² and Cassandra Zhi ³, ¹University at Buffalo, Sisters of Charity Hospital, Buffalo, ²Buffalo Rheumatology and Medicine, Buffalo, ³Dexel University College of Medicine, Philadelphia, PA
Background/Purpose: Current literature evaluating the effect of high Body Mass Index (BMI) on the disease activity of patients with rheumatoid arthritis (RA) is mixed as…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Adel Andemeskel¹, Vivi Feathers ¹, Christine Iannaccone ¹, Jing Cui ¹ and Nancy Shadick ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…
Abstract Number: 469 • 2019 ACR/ARP Annual Meeting
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Susumu Nishiyama¹, Tetsuji Sawada ² and Shigeto Tohma ³, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ³National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: To predict prognosis of patients with rheumatoid arthritis (RA) from the location and the size of affected joints.Methods: Data of 7,776 patients with RA,…
Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting
Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Laura Coates¹, Joseph Merola ², Arthur Kavanaugh ³, Philip Mease ⁴, Owen Davies ⁵, Oscar Irvin-Sellers ⁶, Tommi Nurminen ⁷ and Désirée van der Heijde ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³University of California, San Diego School of Medicine, La Jolla, CA, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁵UCB Pharma, Slough, England, United Kingdom, ⁶UCB Pharma, Slough, UK, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
Abstract Number: 210 • 2018 ACR/ARHP Annual Meeting
Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality
Joshua Baker¹, Harlan Sayles², Bryant R. England³, Ted R. Mikuls⁴ and Kaleb Michaud⁵, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prior studies observed better disease control, quality of life, and physical function among patients with rheumatoid arthritis (RA) who drink alcohol. These studies may…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 1060 • 2018 ACR/ARHP Annual Meeting
Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis
Joong Kyong Ahn¹, Jiwon Hwang², Jaejoon Lee³, Eun-Mi Koh³ and Hoon-Suk Cha³, ¹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Internal Medicine, National Police Hospital, Seoul, Korea, Republic of (South), ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by persistent inflammation and joint damage with a heterogeneous course and different pathogenic mechanisms. Metabolomics,…
Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Gill Wheater², Mohsen Elshahaly³, Janneke Tekstra¹, Y.K. Onno Teng⁴, Floris PJG Lafeber¹, Ching Chang Hwang⁵, Xinyu Liu⁶, Eric H. Sasso⁵ and Jacob van Laar¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, ³Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, ⁴Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁵Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, ⁶Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Michal Cesak⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Barbora Sumova^1,2, Olga Ruzickova^1,6, Herman F Mann^1,7, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Jiri Vencovsky^1,8, Radim Becvar^1,2 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Philip J. Mease¹, Frank Behrens², Dafna D Gladman³, Arthur Kavanaugh⁴, Michele Brunori⁵, Lichen Teng⁵, Benoit Guerette⁵, Rubén Queiro⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California, San Diego, School of Medicine, La Jolla, CA, ⁵Celgene Corporation, Summit, NJ, ⁶Rheum-Derm Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…
Abstract Number: 2889 • 2018 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial
Philip J. Mease¹, Shelly Kafka², Soumya D Chakravarty³, Diane D. Harrison⁴, Kim Hung Lo⁴, Stephen Xu⁴, Elizabeth C Hsia⁵ and Arthur Kavanaugh⁶, ¹Swedish Medical Centre and University of Washington, Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) w/…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].